Enanta Pharmaceuticals to Present at Baird Biotech Discovery Conference

Enanta Pharmaceuticals to Participate in Baird鈥檚 Biotech Discovery Series

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

07/15/2025 - 07:00 AM

WATERTOWN, Mass.--(BUSINESS WIRE)-- (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, July 22 at 1:30 p.m. ET as part of Baird鈥檚 Biotech Discovery Series.

A live webcast of the event will be accessible by visiting the 鈥淓vents and Presentations鈥� section on the 鈥淚nvestors鈥� page of Enanta鈥檚 website at . A replay of the webcast will be available following the event and will be archived for at least 30 days.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta鈥檚 clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing acute and chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET庐 (U.S.) and MAVIRET庐 (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta鈥檚 royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta鈥檚 operations. Please visit for more information.